

Myanmar Support for Pentavalent Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Myanmar							
2. Grant number: 1721-MMR-04c-X							
3. Date of Decision Letter: 19 December 2016							
4. Date of the Partnership Framework Agreement: 4 April 2014							
5. Programme title: New Vaccine Support (NVS), Pentavalent Routine							
6. Vaccine type: Pentavalent							
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 10 dose(s) per vial, LIQUID							
8. Programme duration⁶: 2012 - 2021							
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)							
	2012-2016	2017	2018	2019	2020	2021	Total ⁷
Programme Budget (US\$)	36,300,325 ⁸	4,443,500	3,970,500	3,968,500	3,996,000	3,986,500	56,665,325
10. Vaccine introduction grant (in US\$): Not applicable							
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁹							
Type of supplies to be purchased with Gavi funds in each year		2012-2016		2017			
Number of Pentavalent vaccines doses				3,712,000			
Annual Amounts (US\$)		36,300,325 ¹⁰		4,443,500			
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.							
13. Self-procurement: Not applicable							

⁶ This is the entire duration of the Programme.

⁷ This is the total amount endorsed by Gavi for the entire duration of the Programme.

⁸ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁹ This is the amount that Gavi has approved.

¹⁰ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

14. Co-financing obligations: Reference code: 1721-MMR-04c-X-C

According to the co-financing policy, the Country falls within the group Preparatory transition.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2017	2018	2019	2020
Number of vaccine doses	291,000	291,500	356,000	391,500
Number of AD syringes	249,100			
Number of safety boxes	2,750			
Value of vaccine doses (US\$)	340,629			
Total co-financing payments (US\$) (including freight)	360,500	361,000	441,000	485,000

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements: Not applicable

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

Financial clarifications: The country shall address any recommendations, prioritised needs or strategic actions as described in the High Level Review Panel Report (October 2016).

17. Other conditions: Not applicable

Signed by,

On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
19 December 2016


Barry Greene
Managing Director
Finance & Operations
The GAVI Alliance

20 DECEMBER 2016